244 related articles for article (PubMed ID: 22496163)
1. Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia.
Bhatla T; Wang J; Morrison DJ; Raetz EA; Burke MJ; Brown P; Carroll WL
Blood; 2012 May; 119(22):5201-10. PubMed ID: 22496163
[TBL] [Abstract][Full Text] [Related]
2. A therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed/refractory acute lymphoblastic leukemia.
Burke MJ; Lamba JK; Pounds S; Cao X; Ghodke-Puranik Y; Lindgren BR; Weigel BJ; Verneris MR; Miller JS
Am J Hematol; 2014 Sep; 89(9):889-95. PubMed ID: 24891274
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic inactivation of Notch-Hes pathway in human B-cell acute lymphoblastic leukemia.
Kuang SQ; Fang Z; Zweidler-McKay PA; Yang H; Wei Y; Gonzalez-Cervantes EA; Boumber Y; Garcia-Manero G
PLoS One; 2013; 8(4):e61807. PubMed ID: 23637910
[TBL] [Abstract][Full Text] [Related]
4. p53-independent epigenetic repression of the p21(WAF1) gene in T-cell acute lymphoblastic leukemia.
Davies C; Hogarth LA; Dietrich PA; Bachmann PS; Mackenzie KL; Hall AG; Lock RB
J Biol Chem; 2011 Oct; 286(43):37639-50. PubMed ID: 21903579
[TBL] [Abstract][Full Text] [Related]
5. Highly synergistic effect of sequential treatment with epigenetic and anticancer drugs to overcome drug resistance in breast cancer cells is mediated via activation of p21 gene expression leading to G2/M cycle arrest.
Vijayaraghavalu S; Dermawan JK; Cheriyath V; Labhasetwar V
Mol Pharm; 2013 Jan; 10(1):337-52. PubMed ID: 23215027
[TBL] [Abstract][Full Text] [Related]
6. Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients.
Pera B; Tang T; Marullo R; Yang SN; Ahn H; Patel J; Elstrom R; Ruan J; Furman R; Leonard J; Cerchietti L; Martin P
Clin Epigenetics; 2016; 8():79. PubMed ID: 27453763
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic Combination Therapy for Children With Secondary Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML) and Concurrent Solid Tumor Relapse.
Glasser CL; Lee A; Eslin D; Marks L; Modak S; Glade Bender JL
J Pediatr Hematol Oncol; 2017 Oct; 39(7):560-564. PubMed ID: 28562519
[TBL] [Abstract][Full Text] [Related]
8. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
Ahrens TD; Timme S; Hoeppner J; Ostendorp J; Hembach S; Follo M; Hopt UT; Werner M; Busch H; Boerries M; Lassmann S
Epigenetics; 2015; 10(5):431-45. PubMed ID: 25923331
[TBL] [Abstract][Full Text] [Related]
9. Decitabine-induced apoptosis is derived by Puma and Noxa induction in chronic myeloid leukemia cell line as well as in PBL and is potentiated by SAHA.
Brodská B; Otevřelová P; Holoubek A
Mol Cell Biochem; 2011 Apr; 350(1-2):71-80. PubMed ID: 21153863
[TBL] [Abstract][Full Text] [Related]
10. Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia: biology and therapeutic targeting.
Schafer E; Irizarry R; Negi S; McIntyre E; Small D; Figueroa ME; Melnick A; Brown P
Blood; 2010 Jun; 115(23):4798-809. PubMed ID: 20215641
[TBL] [Abstract][Full Text] [Related]
11. Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo.
Steele N; Finn P; Brown R; Plumb JA
Br J Cancer; 2009 Mar; 100(5):758-63. PubMed ID: 19259094
[TBL] [Abstract][Full Text] [Related]
12. Butyrates and decitabine cooperate to induce histone acetylation and granulocytic maturation of t(8;21) acute myeloid leukemia blasts.
Gozzini A; Santini V
Ann Hematol; 2005 Dec; 84 Suppl 1():54-60. PubMed ID: 16228241
[TBL] [Abstract][Full Text] [Related]
13. Preclinical evaluation of antineoplastic activity of inhibitors of DNA methylation (5-aza-2'-deoxycytidine) and histone deacetylation (trichostatin A, depsipeptide) in combination against myeloid leukemic cells.
Shaker S; Bernstein M; Momparler LF; Momparler RL
Leuk Res; 2003 May; 27(5):437-44. PubMed ID: 12620295
[TBL] [Abstract][Full Text] [Related]
14. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
[TBL] [Abstract][Full Text] [Related]
15. Reprogramming epigenetic silencing: artificial transcription factors synergize with chromatin remodeling drugs to reactivate the tumor suppressor mammary serine protease inhibitor.
Beltran AS; Sun X; Lizardi PM; Blancafort P
Mol Cancer Ther; 2008 May; 7(5):1080-90. PubMed ID: 18483297
[TBL] [Abstract][Full Text] [Related]
16. Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma.
Bensaid D; Blondy T; Deshayes S; Dehame V; Bertrand P; Grégoire M; Errami M; Blanquart C
Clin Epigenetics; 2018; 10():79. PubMed ID: 29946373
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition.
Bachmann PS; Piazza RG; Janes ME; Wong NC; Davies C; Mogavero A; Bhadri VA; Szymanska B; Geninson G; Magistroni V; Cazzaniga G; Biondi A; Miranda-Saavedra D; Göttgens B; Saffery R; Craig JM; Marshall GM; Gambacorti-Passerini C; Pimanda JE; Lock RB
Blood; 2010 Oct; 116(16):3013-22. PubMed ID: 20647567
[TBL] [Abstract][Full Text] [Related]
18. p21(WAF1) modulates drug-induced apoptosis and cell cycle arrest in B-cell precursor acute lymphoblastic leukemia.
Davies C; Hogarth LA; Mackenzie KL; Hall AG; Lock RB
Cell Cycle; 2015; 14(22):3602-12. PubMed ID: 26506264
[TBL] [Abstract][Full Text] [Related]
19. Decitabine and vorinostat cooperate to sensitize colon carcinoma cells to Fas ligand-induced apoptosis in vitro and tumor suppression in vivo.
Yang D; Torres CM; Bardhan K; Zimmerman M; McGaha TL; Liu K
J Immunol; 2012 May; 188(9):4441-9. PubMed ID: 22461695
[TBL] [Abstract][Full Text] [Related]
20. Genistein cooperates with the histone deacetylase inhibitor vorinostat to induce cell death in prostate cancer cells.
Phillip CJ; Giardina CK; Bilir B; Cutler DJ; Lai YH; Kucuk O; Moreno CS
BMC Cancer; 2012 Apr; 12():145. PubMed ID: 22494660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
